Verified· 2 sources

Atopia Therapeutics SA

Summary

About the company

Atopia Therapeutics SA is developing a disease‑modifying therapy for asthma and other allergic diseases. Its lead candidate, ATP‑R13, is a patented recombinant protein derived from a Helicobacter pylori molecule intended for oral administration to modulate immune tolerance and reduce inflammation; the company holds an exclusive worldwide licence from the University of Zurich and is conducting IND‑enabling activities.

AI-generated

Offering

Products & services

Industry:Pharmaceutical Industry

✓ Offered3

Development of a disease-modifying therapy for asthma and allergic diseases

Development of a first-in-class, disease-modifying therapy for asthma and other allergic diseases based on a molecule from Helicobacter pylori.

Development of ATP-R13

Development of the patented, optimized recombinant protein version ATP-R13 as an orally administered immunomodulatory active ingredient to reduce inflammation and allergy symptoms.

Partnerships for clinical and preclinical development

Collaboration with industrial and financial partners for the next development phases, including use of internal expertise and the network of specialists and CROs.

Outbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub

Atopia Therapeutics SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

Atopia Therapeutics SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

No knowledge articles yet

Atopia Therapeutics SA in comparison

Industry comparisons are coming soon

Similar companies